Results 221 to 230 of about 1,369,314 (252)

Systemic medications associate with surgically treated cataract among adults over 50 years in Finland

open access: yesActa Ophthalmologica, Volume 104, Issue 6, Page e630-e647, September 2026.
Abstract Purpose To identify associations between systemic drugs and cataract surgery in Finland. Methods A historic cohort study based on administrative data. Endpoint event was cataract surgery. Use of drugs in question was based on redeemed prescriptions and consisted of 156 drugs.
Antti Riikonen   +3 more
wiley   +1 more source

Prenylated Isoflavones Originating from East African Medicinal Plants Selectively Modulate the α-Glucosidase from <i>Saccharomyces cerevisiae</i>. [PDF]

open access: yesJ Nat Prod
Lüersen K   +9 more
europepmc   +1 more source

Simplified Switching to Once‐Weekly Insulin Icodec Without an Initial One‐Time Additional Dose Versus Once‐Daily Insulin Glargine U100 in Basal Insulin‐Treated Type 2 Diabetes (ONWARDS 10): A Randomised Controlled Trial

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 7791-7801, September 2026.
ABSTRACT Aims ONWARDS 10 assessed switching from daily basal insulins to once‐weekly insulin icodec without a one‐time additional dose at first injection. Materials and Methods In this treat‐to‐target, open‐label, 26‐week, phase 3b trial, adults with basal‐insulin‐treated type 2 diabetes (T2D) with glycated haemoglobin [HbA1c] 7.0%–10.0% were ...
Julio Rosenstock   +5 more
wiley   +1 more source

Potent and selective α-glucosidase inhibition by coumarin-triazole conjugates: design, <i>in vivo</i> evaluation, and computational insights. [PDF]

open access: yesRSC Adv
Sadeghi Moghadam M   +11 more
europepmc   +1 more source

Glucagon‐Like Peptide‐1 Receptor Agonists and Incident Major Adverse Liver Outcomes in People With Type 2 Diabetes and Metabolic Dysfunction‐Associated Steatotic Liver Disease

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8277-8287, September 2026.
ABSTRACT Aims Treatment options for metabolic dysfunction‐associated steatotic liver disease (MASLD) are limited. While glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) and sodium‐glucose cotransporter‐2 (SGLT‐2) inhibitors improve cardiovascular outcomes, comparative effectiveness on liver‐related outcomes remains unclear.
Gregor A. Maier   +4 more
wiley   +1 more source

Comprehensive Review on Green Transformation of Organic Waste Into Bioenergy Using Microbial Enzymes: Advances, Challenges, and Future Strategies

open access: yesGCB Bioenergy, Volume 18, Issue 9, September 2026.
Microbial enzyme‐mediated biorefineries enable the sustainable conversion of organic waste into renewable bioenergy and value‐added products. Recent advances on enzymatic pretreatment, enzyme cocktails, and hybrid processing enhance biogas, bioethanol, and biodiesel production, along with supporting efficient waste valorization, circular bioeconomy ...
Divya Divakaran   +6 more
wiley   +1 more source

Antidiabetic and Antioxidant Potential of a New Bisglyceride Derivative Together with Other Compounds from the Root Bark of <i>Pithecellobium dulce</i>: In Vitro and In Silico Studies. [PDF]

open access: yesMolecules
Messah GN   +14 more
europepmc   +1 more source

Neutrophil Secretory Proteins Inhibit Calcium Oxalate Crystallisation and Crystal Growth, but Promote Crystal Aggregation

open access: yesImmunology, Volume 179, Issue 1, Page 101-117, September 2026.
Calcium oxalate monohydrate (COM) crystals cause changes in the secretion of 29 proteins from neutrophil‐like cells, including those involved in neutrophil immune activation and intracellular metabolic adaptation. The neutrophil secreted proteins (secretome) also inhibit calcium oxalate crystallisation and crystal growth, but promote crystal ...
Chanettee Lertprapai   +2 more
wiley   +1 more source

Carbazole-Based Ester Derivatives as Potential α-Glucosidase Inhibitors; Synthesis, Biological Evaluation, and Molecular Docking Studies. [PDF]

open access: yesMolecules
Kaya L   +10 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy